Table 3.
Lesion characteristics
| Lesion ID | AR | Size (mm) | SUVmax mMR 20-min |
SUVmax Vision OSEM-TOF |
ACmax mMR 20-min (kBq/mL) |
ACmax Vision OSEM-TOF (kBq/mL) |
SBR mMR 20-min |
|---|---|---|---|---|---|---|---|
| 1 | CLN | 13 | 15.2 | 14.0 | 4,6 | 4.2 | 42.6 |
| 2 | CLN | 17 | 8.8 | 9.9 | 2.6 | 3.5 | 25.7 |
| 3 | CLN | 9 | 3.1 | 3.4 | 0.9 | 1.0 | 10.7 |
| 4 | CLN | 7 | 2.3 | – | 0.8 | – | 12.6 |
| 5 | Bone | < 6 | 8.4a | 3.1 | 3.2a | 1.2 | 14.4 |
| 6 | TB | 16 | 10.2 | 9.9 | 4.7 | 4.6 | 29.6 |
| 7 | CLN | 6 | 3.0 | 2.2 | 1.4 | 1.0 | 8.4 |
| 8 | TB | <6 | 5.6 | 5.1 | 2.4 | 2.8 | 7.1 |
| 9 | CLN | 4 | 3.0 | 1.8 | 1.3 | 0.9 | 6.5 |
AR Anatomical region, CLN Cervical lymph node, TB Thyroid bed, SBR Signal-to-background ratio (only reported for the 20-min acquisition on the mMR, in which all lesions were detectable)
aPotentially artificially elevated activity concentration in PET/MR attenuation correction, as the bone lesion was osteolytic